Skip to main content

Table 2 Summary of antimicrobial co-resistance rates determined for a) E . coli, b) K . pneumoniae, c) K . oxytoca, d) E . cloacae, and e) P . aeruginosa

From: Antimicrobial co-resistance patterns of gram-negative bacilli isolated from bloodstream infections: a longitudinal epidemiological study from 2002–2011

a) E. coli

      

No. of isolates (n)

Resistance to

Co-resistance rate with antibiotic (%)

2002-06

 

Ceftriaxone

Ciprofloxacin

Pip-tazo

TMP-SMX

Tic-clav

44

Ceftriaxone

 

73

14

59

59

194

Ciprofloxacin

16

 

8

62

31

3

Pip-tazo

33

67

 

67

nd

193

TMP-SMX

13

63

8

 

31

91

Tic-clav

29

67

nd

66

 

2007-11

      

146

Ceftriaxone

 

73

18

72

48

357

Ciprofloxacin

30

 

10

58

26

28

Pip-tazo

57

71

 

79

nd

373

TMP-SMX

28

56

10

 

27

64

Tic-clav

42

61

nd

61

 

2002-11

      

190

Ceftriaxone

 

73

18

69

53

551

Ciprofloxacin

25

 

10

60

29

31

Pip-tazo

55

71

 

77

nd

566

TMP-SMX

23

58

9

 

30

155

Tic-clav

34

65

nd

64

 

b) K. pneumoniae

      

No. of isolates (n)

Resistance to

Co-resistance rate with antibiotic (%)

2002-2011

 

Ceftriaxone

Ciprofloxacin

Pip-tazo

TMP-SMX

Tic-clav

20

Ceftriaxone

 

60

35

83

53

54

Ciprofloxacin

22

 

22

46

29

10

Pip-tazo

60

50

 

40

nd

44

TMP-SMX

30

57

16

 

37

19

Tic-clav

26

58

nd

53

 

c) K. oxytoca

      

No. of isolates (n)

Resistance to

Co-resistance rate with antibiotic (%)

2002-2011

 

Ceftriaxone

Ciprofloxacin

Pip-tazo

TMP-SMX

Tic-clav

8

Ceftriaxone

 

38

20

25

50

5

Ciprofloxacin

60

 

0

20

25

2

Pip-tazo

50

0

 

0

nd

5

TMP-SMX

40

20

0

 

100

3

Tic-clav

67

33

nd

33

 

d) E. cloacae

      

No. of isolates (n)

Resistance to

Co-resistance rate with antibiotic (%)

2002-2011

 

Ceftriaxone

Ciprofloxacin

Pip-tazo

TMP-SMX

Tic-clav

43

Ceftriaxone

 

26

47

37

81

17

Ciprofloxacin

65

 

17

59

91

9

Pip-tazo

100

11

 

11

nd

24

TMP-SMX

67

42

6

 

80

33

Tic-clav

67

30

nd

24

 

e) P. aeruginosa

      

No. of isolates (n)

Resistance to

Co-resistance rate with antibiotic (%)

2002-2011

 

Ceftazidime

Ciprofloxacin

Pip-tazo

Imipenem

Gentamicin

11

Ceftazidime

 

45

50

27

9

22

Ciprofloxacin

23

 

24

23

23

6

Pip-tazo

83

67

 

33

33

13

Imipenem

23

38

18

 

23

9

Gentamicin

11

56

29

33

 
  1. Co-resistance rates were analyzed as a summary of isolates from 2002–2011 except for E. coli, where it was possible to analyze two time periods from 2002–06 and 2007–11 due to higher isolate numbers. Co-resistance rates are rounded to the nearest percent, and those that are ≥50% are highlighted in bold font. Note: Pip-tazo is piperacillin-tazobactam, TMP-SMX is trimethoprim-sulfamethoxazole, Tic-clav is ticarcillin-clavulanate; nd is not determined as isolates did not consistently have both Pip-tazo and Tic-clav susceptibilities reported.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us